CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-10-17): New scoring system rules out advanced liver fibrosis

Clinical

New scoring system rules out advanced liver fibrosis

Last Updated: 2008-10-17 17:27:26 -0400 (Reuters Health)

NEW YORK (Reuters Health) - A simple scoring system accurately identifies patients with nonalcoholic fatty liver disease (NAFLD) who don't have advanced disease, according to a report in the October issue of Gut.

The "BARD" score was developed to incorporate 1 point for a BMI of at least 28, 2 points for AST/ALT ratio of 0.80 or greater, and 1 point for diabetes.

A BARD score of 2-4 has a positive predictive value of 43% and a negative predictive value of 96% for detecting stage 3-4 fibrosis, the researchers note.

"If the BARD score is < 2, physicians can be reassured the patient does not have advanced liver disease, and if the patient has a BARD score of 2 or greater, they really need to be concerned and take action," Dr. Stephen A. Harrison from Brooke Army Medical Center, San Antonio, Texas, told Reuters Health.

Dr. Harrison and colleagues defined the clinical, laboratory, and histopathological characteristics of 827 patients with biopsy-proven NAFLD and developed a simple clinical scoring system for identifying patients with advanced fibrosis.

Compared with patients having fatty liver alone, patients with nonalcoholic steatohepatitis (NASH) were older, heavier, predominantly female, hypertensive, diabetic, insulin resistant and had a higher ALT and AST, the authors report.

Patients with stage 3-4 fibrosis were also likelier than patients without fibrosis to be older, female, diabetic, insulin resistant, and to have higher AST/ALT ratios.

Based on additional analyses, the investigators found that the BARD score was at least equivalent to the more complex NAFLD fibrosis score in excluding patients with advanced fibrosis.

A simple scoring system that relies on only three clinical features was validated in a large group of patients. BARD "may assist clinicians in targeting those patients in need of liver biopsies to confirm the diagnosis and guide management, particularly among patients with diabetes," the authors conclude.

Gut 2008;57:1441-1447.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.